Rationale for the intraperitoneal administration of Paclitaxel (Taxol®) in the treatment of ovarian cancer Journal Article
| Authors: | Markman, M.; Francis, P.; Rowinsky, E.; Hakes, T.; Reichman, B.; Jones, W.; Lewis, J. L.; Rubin, S.; Curtin, J.; Barakat, R.; Phillips, M.; Hoskins, W. |
| Article Title: | Rationale for the intraperitoneal administration of Paclitaxel (Taxol®) in the treatment of ovarian cancer |
| Abstract: | Paclitaxel (Taxol(R)) has several characteristics that make it an interesting agent for intraperitoneal administration, including activity in platinum-refractory ovarian cancer, cell cycle specificity for cytotoxicity, non-vesicant property, bulky structure, and metabolism in the liver. A recently completed phase I trial of intraperitoneal paclitaxel has confirmed a >3-log pharmacokinetic advantage for peritoneal cavity exposure compared with systemic compartment exposure. A phase II efficacy trial of intraperitoneal paclitaxel in ovarian cancer patients failing front-line chemotherapy is planned by the Gynecologic Oncology Group. |
| Keywords: | cisplatin; paclitaxel; chemotherapy; ovarian cancer; carcinoma; phase-i; agent |
| Journal Title: | International Journal of Gynecological Cancer |
| Volume: | 4 |
| Issue: | Suppl. 1 |
| ISSN: | 1048-891X |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 1994-01-01 |
| Start Page: | 19 |
| End Page: | 22 |
| Language: | English |
| ACCESSION: | WOS:A1994PV84900005 |
| PROVIDER: | wos |
| Notes: | Source: Wos |
